TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial of the Use of Antenatal Corticosteroids in Developing Countries
Brief Summary: Multi-country two-arm, parallel cluster randomized controlled trial to reduce neonatal mortality through increasing the rate of antenatal corticosteroid administration to eligible women.


Options:
A: Arm Label: ACS (Group 1); Type: ACTIVE_COMPARATOR; Interventions: Drug: Betamethason Sodium Phosphate | Arm Label: Placebo (Group 2); Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Betamethason Sodium Phosphate; Assigned to Arm(s): ACS (Group 1) | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Placebo (Group 2)
B: Intervention Type: DRUG; Name: Betamethasone(Celestone soluspan) and Dexamethasone; Assigned to Arm(s): N/A
C: Arm Label: 12mg betamethasone+12mg betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: betamethasone 24 mg | Arm Label: 12 mg betamethasone+ placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 12mg betamethasone +placebo | Intervention Type: DRUG; Name: betamethasone 24 mg; Assigned to Arm(s): 12mg betamethasone+12mg betamethasone | Intervention Type: DRUG; Name: 12mg betamethasone +placebo; Assigned to Arm(s): 12 mg betamethasone+ placebo
D: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Increasing use of Antenatal Corticosteroids (ACS) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Increasing use of Antenatal Corticosteroids (ACS); Assigned to Arm(s): Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial of the Use of Antenatal Corticosteroids in Developing Countries
Brief Summary: Multi-country two-arm, parallel cluster randomized controlled trial to reduce neonatal mortality through increasing the rate of antenatal corticosteroid administration to eligible women.


Options:
A: Intervention Type: DRUG; Name: Betamethasone sodium phos (drug); Assigned to Arm(s): N/A
B: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Increasing use of Antenatal Corticosteroids (ACS) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Increasing use of Antenatal Corticosteroids (ACS); Assigned to Arm(s): Intervention
C: Arm Label: ACS (Group 1); Type: ACTIVE_COMPARATOR; Interventions: Drug: Betamethason Sodium Phosphate | Arm Label: Placebo (Group 2); Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Betamethason Sodium Phosphate; Assigned to Arm(s): ACS (Group 1) | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Placebo (Group 2)
D: Arm Label: 12mg betamethasone+12mg betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: betamethasone 24 mg | Arm Label: 12 mg betamethasone+ placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 12mg betamethasone +placebo | Intervention Type: DRUG; Name: betamethasone 24 mg; Assigned to Arm(s): 12mg betamethasone+12mg betamethasone | Intervention Type: DRUG; Name: 12mg betamethasone +placebo; Assigned to Arm(s): 12 mg betamethasone+ placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial of the Use of Antenatal Corticosteroids in Developing Countries
Brief Summary: Multi-country two-arm, parallel cluster randomized controlled trial to reduce neonatal mortality through increasing the rate of antenatal corticosteroid administration to eligible women.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: betamethasone | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: betamethasone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B
B: Arm Label: ACS (Group 1); Type: ACTIVE_COMPARATOR; Interventions: Drug: Betamethason Sodium Phosphate | Arm Label: Placebo (Group 2); Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Betamethason Sodium Phosphate; Assigned to Arm(s): ACS (Group 1) | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Placebo (Group 2)
C: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Increasing use of Antenatal Corticosteroids (ACS) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Increasing use of Antenatal Corticosteroids (ACS); Assigned to Arm(s): Intervention
D: Arm Label: Betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Betamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Betamethasone; Assigned to Arm(s): Betamethasone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial of the Use of Antenatal Corticosteroids in Developing Countries
Brief Summary: Multi-country two-arm, parallel cluster randomized controlled trial to reduce neonatal mortality through increasing the rate of antenatal corticosteroid administration to eligible women.


Options:
A: Arm Label: Registry Cohort; Type: N/A; Interventions: Other: No Intervention | Intervention Type: OTHER; Name: No Intervention; Assigned to Arm(s): Registry Cohort
B: Arm Label: Betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Betamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Betamethasone; Assigned to Arm(s): Betamethasone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: ACS (Group 1); Type: ACTIVE_COMPARATOR; Interventions: Drug: Betamethason Sodium Phosphate | Arm Label: Placebo (Group 2); Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Betamethason Sodium Phosphate; Assigned to Arm(s): ACS (Group 1) | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Placebo (Group 2)
D: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Increasing use of Antenatal Corticosteroids (ACS) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Increasing use of Antenatal Corticosteroids (ACS); Assigned to Arm(s): Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial of the Use of Antenatal Corticosteroids in Developing Countries
Brief Summary: Multi-country two-arm, parallel cluster randomized controlled trial to reduce neonatal mortality through increasing the rate of antenatal corticosteroid administration to eligible women.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: betamethasone | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: betamethasone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B
B: Arm Label: Betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Betamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Betamethasone; Assigned to Arm(s): Betamethasone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Betamethasone | Intervention Type: DRUG; Name: Betamethasone; Assigned to Arm(s): A
D: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Increasing use of Antenatal Corticosteroids (ACS) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Increasing use of Antenatal Corticosteroids (ACS); Assigned to Arm(s): Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial of the Use of Antenatal Corticosteroids in Developing Countries
Brief Summary: Multi-country two-arm, parallel cluster randomized controlled trial to reduce neonatal mortality through increasing the rate of antenatal corticosteroid administration to eligible women.


Options:
A: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Increasing use of Antenatal Corticosteroids (ACS) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Increasing use of Antenatal Corticosteroids (ACS); Assigned to Arm(s): Intervention
B: Intervention Type: DRUG; Name: Co-Trimoxazole; TMP-SMZ; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Newborn Thermal Care Practice; Assigned to Arm(s): N/A
D: Arm Label: experimental; Type: EXPERIMENTAL; Interventions: Behavioral: training | Intervention Type: BEHAVIORAL; Name: training; Assigned to Arm(s): experimental

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial of the Use of Antenatal Corticosteroids in Developing Countries
Brief Summary: Multi-country two-arm, parallel cluster randomized controlled trial to reduce neonatal mortality through increasing the rate of antenatal corticosteroid administration to eligible women.


Options:
A: Intervention Type: DRUG; Name: Caffeine citrate injection; Assigned to Arm(s): N/A
B: Arm Label: Betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Betamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Betamethasone; Assigned to Arm(s): Betamethasone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: ACS (Group 1); Type: ACTIVE_COMPARATOR; Interventions: Drug: Betamethason Sodium Phosphate | Arm Label: Placebo (Group 2); Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Betamethason Sodium Phosphate; Assigned to Arm(s): ACS (Group 1) | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Placebo (Group 2)
D: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Increasing use of Antenatal Corticosteroids (ACS) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Increasing use of Antenatal Corticosteroids (ACS); Assigned to Arm(s): Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial of the Use of Antenatal Corticosteroids in Developing Countries
Brief Summary: Multi-country two-arm, parallel cluster randomized controlled trial to reduce neonatal mortality through increasing the rate of antenatal corticosteroid administration to eligible women.


Options:
A: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Increasing use of Antenatal Corticosteroids (ACS) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Increasing use of Antenatal Corticosteroids (ACS); Assigned to Arm(s): Intervention
B: Arm Label: Ibuprofen group; Type: N/A; Interventions: Drug: Ibuprofen (Sanofi, Istanbul, Turkey) | Arm Label: Paracetamol group; Type: N/A; Interventions: Drug: Paracetamol (GlaxoSmithKline, Istanbul, Turkey) | Intervention Type: DRUG; Name: Ibuprofen (Sanofi, Istanbul, Turkey); Assigned to Arm(s): Ibuprofen group | Intervention Type: DRUG; Name: Paracetamol (GlaxoSmithKline, Istanbul, Turkey); Assigned to Arm(s): Paracetamol group
C: Arm Label: Paracetamol; Type: EXPERIMENTAL; Interventions: Drug: Paracetamol | Arm Label: Ibuprofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Paracetamol | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Ibuprofen
D: Arm Label: Paracetamol effect on ductus; Type: EXPERIMENTAL; Interventions: Drug: paracetamol, Drug: 0.45 % saline solution | Arm Label: Paracetamol effect on pain; Type: EXPERIMENTAL; Interventions: Drug: paracetamol, Drug: 0.45 % saline solution | Intervention Type: DRUG; Name: paracetamol; Assigned to Arm(s): Paracetamol effect on ductus, Paracetamol effect on pain | Intervention Type: DRUG; Name: 0.45 % saline solution; Assigned to Arm(s): Paracetamol effect on ductus, Paracetamol effect on pain

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial of the Use of Antenatal Corticosteroids in Developing Countries
Brief Summary: Multi-country two-arm, parallel cluster randomized controlled trial to reduce neonatal mortality through increasing the rate of antenatal corticosteroid administration to eligible women.


Options:
A: Arm Label: ACS (Group 1); Type: ACTIVE_COMPARATOR; Interventions: Drug: Betamethason Sodium Phosphate | Arm Label: Placebo (Group 2); Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Betamethason Sodium Phosphate; Assigned to Arm(s): ACS (Group 1) | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Placebo (Group 2)
B: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Increasing use of Antenatal Corticosteroids (ACS) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Increasing use of Antenatal Corticosteroids (ACS); Assigned to Arm(s): Intervention
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Very early surfactant and bubble NCPAP | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: bubble NCPAP | Intervention Type: OTHER; Name: Very early surfactant and bubble NCPAP; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: bubble NCPAP; Assigned to Arm(s): 2
D: Arm Label: Betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Betamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Betamethasone; Assigned to Arm(s): Betamethasone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Complementary Feeding - A Global Network Cluster Randomized Controlled Trial
Brief Summary: The specific aims of this project is to determine the impact of a daily intake of one half ounce of lyophilized meat between 6-18 months of age (0.5 oz for 6-12 mo; 0.75 oz for 12-18 mo) on linear growth velocity, zinc and iron intakes and status, brain growth and neurocognitive development, and infectious disease morbidity in populations traditionally dependent on non-micronutrient fortified plant foods for complementary feeding.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Lyophilized meat | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Cereal | Intervention Type: OTHER; Name: Lyophilized meat; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Cereal; Assigned to Arm(s): 2
B: Arm Label: Fe, Zn, Fe+Zn, Placebo; Type: N/A; Interventions: N/A
C: Arm Label: Zinc; Type: EXPERIMENTAL; Interventions: Drug: Drug: Zinc (zinc sulphate) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Drug: Zinc (zinc sulphate); Assigned to Arm(s): Zinc | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: ZINC; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Complementary Feeding - A Global Network Cluster Randomized Controlled Trial
Brief Summary: The specific aims of this project is to determine the impact of a daily intake of one half ounce of lyophilized meat between 6-18 months of age (0.5 oz for 6-12 mo; 0.75 oz for 12-18 mo) on linear growth velocity, zinc and iron intakes and status, brain growth and neurocognitive development, and infectious disease morbidity in populations traditionally dependent on non-micronutrient fortified plant foods for complementary feeding.


Options:
A: Arm Label: Dietary supplement; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Corn Soya Blend+ | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Corn Soya Blend+; Assigned to Arm(s): Dietary supplement
B: Intervention Type: DRUG; Name: NaFeEDTA, Electrolytic Iron; Assigned to Arm(s): N/A
C: Arm Label: Maize porridge with Amaranth; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Maize and Amaranth | Arm Label: Maize flour with multiple micronutrients; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Maize and Amaranth | Arm Label: Maize Porridge; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Maize and Amaranth | Intervention Type: DIETARY_SUPPLEMENT; Name: Maize and Amaranth; Assigned to Arm(s): Maize Porridge, Maize flour with multiple micronutrients, Maize porridge with Amaranth
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Lyophilized meat | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Cereal | Intervention Type: OTHER; Name: Lyophilized meat; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Cereal; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Complementary Feeding - A Global Network Cluster Randomized Controlled Trial
Brief Summary: The specific aims of this project is to determine the impact of a daily intake of one half ounce of lyophilized meat between 6-18 months of age (0.5 oz for 6-12 mo; 0.75 oz for 12-18 mo) on linear growth velocity, zinc and iron intakes and status, brain growth and neurocognitive development, and infectious disease morbidity in populations traditionally dependent on non-micronutrient fortified plant foods for complementary feeding.


Options:
A: Arm Label: Traditional Diet; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Cereal; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Caterpillar Cereal | Intervention Type: DIETARY_SUPPLEMENT; Name: Caterpillar Cereal; Assigned to Arm(s): Cereal
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Lyophilized meat | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Cereal | Intervention Type: OTHER; Name: Lyophilized meat; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Cereal; Assigned to Arm(s): 2
C: Arm Label: Meat; Type: ACTIVE_COMPARATOR; Interventions: Other: Meat | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Cereal | Arm Label: Fortified rice cereal; Type: ACTIVE_COMPARATOR; Interventions: Other: fortified rice cereal | Intervention Type: OTHER; Name: Meat; Assigned to Arm(s): Meat | Intervention Type: OTHER; Name: Cereal; Assigned to Arm(s): Control | Intervention Type: OTHER; Name: fortified rice cereal; Assigned to Arm(s): Fortified rice cereal
D: Arm Label: meat group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: a high-protein complementary diet with meat | Arm Label: dairy group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: a high-protein complementary diet with dairy | Intervention Type: BEHAVIORAL; Name: a high-protein complementary diet with meat; Assigned to Arm(s): meat group | Intervention Type: BEHAVIORAL; Name: a high-protein complementary diet with dairy; Assigned to Arm(s): dairy group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Complementary Feeding - A Global Network Cluster Randomized Controlled Trial
Brief Summary: The specific aims of this project is to determine the impact of a daily intake of one half ounce of lyophilized meat between 6-18 months of age (0.5 oz for 6-12 mo; 0.75 oz for 12-18 mo) on linear growth velocity, zinc and iron intakes and status, brain growth and neurocognitive development, and infectious disease morbidity in populations traditionally dependent on non-micronutrient fortified plant foods for complementary feeding.


Options:
A: Arm Label: Food supplement (FS); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Food supplement enriched with multiple micronutrients | Arm Label: UNIMMAP; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: UNIMMAP - multiple micronutrients | Intervention Type: DIETARY_SUPPLEMENT; Name: UNIMMAP - multiple micronutrients; Assigned to Arm(s): UNIMMAP | Intervention Type: DIETARY_SUPPLEMENT; Name: Food supplement enriched with multiple micronutrients; Assigned to Arm(s): Food supplement (FS)
B: Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Nutritional supplement; Type: EXPERIMENTAL; Interventions: Other: Nutritional supplement | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: OTHER; Name: Nutritional supplement; Assigned to Arm(s): Nutritional supplement | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Lyophilized meat | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Cereal | Intervention Type: OTHER; Name: Lyophilized meat; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Cereal; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Micronutrient (Zinc and Iron) fortification; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Pre and Probiotic fortification; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of Stress Levels in Consumers Using Ovulation Tests in Order to Conceive
Brief Summary: Approximately 150 female volunteers wishing to become pregnant will be recruited via web recruitment from around the UK and randomised 1:1 to receive Clearblue Digital ovulation tests (active arm) or no aid to conception (control arm) for 2 full menstrual cycles. All volunteers will complete study questionnaires and provide a urine sample at designated time points though out the menstrual cycle.

A sub-arm to this study, applied the same protocol to women in an infertility treatment setting; Royal Hallamshire Hospital, Sheffield. Additional exclusion criteria were applied to this cohort; had regular menstrual cycles between 25 and 35 days, and who did not have a diagnosis of bilateral or unilateral tubal blockage, documented anovulation or severe male-factor infertility (with \<5 million motile sperm per ejaculate). For this arm, the protocol was reviewed by Sheffield Research Ethics Committee 09/H1308/134.


Options:
A: Arm Label: Electronic hormonal fertility monitoring; Type: EXPERIMENTAL; Interventions: Behavioral: Electronic hormonal fertility monitoring | Arm Label: Cervical mucus monitoring; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-monitoring | Intervention Type: BEHAVIORAL; Name: Electronic hormonal fertility monitoring; Assigned to Arm(s): Electronic hormonal fertility monitoring | Intervention Type: BEHAVIORAL; Name: Self-monitoring; Assigned to Arm(s): Cervical mucus monitoring
B: Arm Label: every other day; Type: EXPERIMENTAL; Interventions: Other: health educational video | Arm Label: fertile window; Type: EXPERIMENTAL; Interventions: Other: health educational video | Arm Label: CG; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: health educational video; Assigned to Arm(s): every other day, fertile window
C: Arm Label: Active; Type: N/A; Interventions: N/A | Arm Label: Control; Type: N/A; Interventions: N/A
D: Arm Label: sample collection; Type: OTHER; Interventions: Other: Ovulation predictions products | Intervention Type: OTHER; Name: Ovulation predictions products; Assigned to Arm(s): sample collection

Answer: C